Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Zhigen Pharmaceutical & Technology Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner, reflecting a highly focused point of prosecution. The data also shows that this work is contained within 1 distinct art unit, which limits the administrative variety the company faces in its current patent applications.
The busiest examiner for this portfolio is AGGARWAL, SAHIL CHANDER, who is handling 1 pending office action. Because the total number of pending office actions for the company is 1, this specific examiner is responsible for the entirety of the company's active prosecution. This creates a situation where the outcome of the company's current patent efforts is tied to the review of this single individual.
Practitioners should note that the concentration of 1 pending office action within 1 art unit and under 1 examiner simplifies the monitoring process. However, it also means there is no diversification of risk across different examiners or technology groups. The specific tendencies of AGGARWAL, SAHIL CHANDER will be the primary factor in the resolution of the 1 pending action currently on the docket.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18843972 | COMPOUND USED AS TYK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | AGGARWAL, SAHIL CHANDER | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843972 | COMPOUND USED AS TYK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | AGGARWAL, SAHIL CHANDER | 1623 | §101§103§112 | Non-Final OA | — | Pending | Sep 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Zhigen Pharmaceutical & Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sahil Chander Aggarwal has the most, with 1 of Shanghai Zhigen Pharmaceutical & Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
